The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Honoraria - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Sharp & Dohme; MSD; Novartis; Pfizer; Roche
 
Consulting or Advisory Role - ABBVIE; AstraZeneca; Blueprint Medicines; BOEHRINGER INGELHEIM; BRISTOL-MYERS SQUIBB; Guardant Health; JANSSEN; LILLY; MERCK KGaA; MERCK SHARP & DOHME; NOVARTIS; PFIZER; Roche; SAMSUNG; TAKEDA
Speakers' Bureau - AstraZeneca; BRISTOL-MYERS SQUIBB; LILLY; MEDSCAPE; Merck Sharp & Dohme; NOVARTIS; PFIZER; prIME ONCOLOGY; ROCHE; TAKEDA; touchIME
Research Funding - Grant for Oncology Innovation; Merck
Other Relationship - GRÍFOLS
Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Incyte; Inivata; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Shirish M. Gadgeel
Honoraria - AstraZeneca; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Novocure; Takeda; Xcovery
Research Funding - Aeglea Biotherapeutics (Inst); ARIAD/Takeda (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Lycera (Inst); Merck; Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck
Other Relationship - AstraZeneca
 
Delvys Rodriguez-Abreu
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche
 
Enriqueta Felip
No Relationships to Disclose
 
Emilio Esteban
Travel, Accommodations, Expenses - Pfizer/EMD Serono; Pfizer/EMD Serono
 
Giovanna Speranza
No Relationships to Disclose
 
Maximilian Hochmair
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche; Takeda
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Actuate Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Vyriad (Inst)
 
Edward B. Garon
Consulting or Advisory Role - Dracen; EMD Serono; GlaxoSmithKline; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Rina Hui
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Novartis; Roche
 
Naoyuki Nogami
No Relationships to Disclose
 
Razvan Cristescu
No Relationships to Disclose
 
Michael Morrissey
No Relationships to Disclose
 
Andrey Loboda
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Julie Kobie
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Mark Ayers
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Bilal Piperdi
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Maria Catherine Pietanza
Employment - Merck
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Alexandra Snyder
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Martin Reck
No Relationships to Disclose